Zobrazeno 1 - 10
of 241
pro vyhledávání: '"DE LA Pinta C"'
Autor:
López-Gil JC; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Department of Biochemistry, Autónoma University of Madrid (UAM), Madrid, Spain., García-Silva S; Microenvironment and Metastasis Group, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain bsainz@iib.uam.es sgsilva@cnio.es christopher.heeschen@icloud.com., Ruiz-Cañas L; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Biobanco Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Navarro D; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Department of Biochemistry, Autónoma University of Madrid (UAM), Madrid, Spain., Palencia-Campos A; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Giráldez-Trujillo A; Grupo de Oncología Cutánea, Servicio de Anatomía Patológica, Hospiral Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain., Earl J; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Área Cáncer, Centro de Investigación Biomédica en Red (CIBERONC), ISCIII, Madrid, Spain., Dorado J; Stem Cells and Cancer Group, Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Gómez-López G; Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Monfort-Vengut A; Cell Cycle and Cancer Biomarkers Laboratory, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain., Alcalá S; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.; Department of Biochemistry, Autónoma University of Madrid (UAM), Madrid, Spain., Gaida MM; Institute of Pathology, JGU-Mainz, University Medical Center Mainz, Mainz, Germany.; TRON, JGU-Mainz, Translational Oncology at the University Medical Center, Mainz, Germany.; Research Center for Immunotherapy, JGU-Mainz, University Medical Center Mainz, Mainz, Germany., García-Mulero S; Department of Pathology and Experimental Therapy, Universidad de Barcelona Facultad de Medicina y Ciencias de La Salud, Barcelona, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), IDIBELL, Barcelona, Spain., Cabezas-Sáinz P; Department of Zoology, Genetics and Physical Anthropology, Veterinary Faculty, Universidade de Santiago de Compostela, Lugo, Spain., Batres-Ramos S; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Barreto E; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Área Cáncer, Centro de Investigación Biomédica en Red (CIBERONC), ISCIII, Madrid, Spain.; School of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Spain., Sánchez-Tomero P; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain.; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Vallespinós M; Stem Cells and Cancer Group, Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Ambler L; Barts Cancer Institute, Queen Mary University of London, London, UK., Lin ML; Barts Cancer Institute, Queen Mary University of London, London, UK., Aicher A; Precision Immunotherapy, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan., García García de Paredes A; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Gastroenterology and Hepatology, Hospital Universitario Ramon y Cajal, Madrid, Spain., de la Pinta C; Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Sanjuanbenito A; Área Cáncer, Centro de Investigación Biomédica en Red (CIBERONC), ISCIII, Madrid, Spain.; Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramon y Cajal, Madrid, Spain., Ruz-Caracuel I; Área Cáncer, Centro de Investigación Biomédica en Red (CIBERONC), ISCIII, Madrid, Spain.; Ramon y Cajal University Hospital Anatomy Pathology Service, Madrid, Spain.; Molecular Pathology of Cancer Group, Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Rodríguez-Garrote M; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Área Cáncer, Centro de Investigación Biomédica en Red (CIBERONC), ISCIII, Madrid, Spain.; Medical Oncology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain., Guerra C; Experimental Oncology Group, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Carrato A; Área Cáncer, Centro de Investigación Biomédica en Red (CIBERONC), ISCIII, Madrid, Spain.; Medical Oncology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain., de Cárcer G; Cell Cycle and Cancer Biomarkers Laboratory, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain., Sánchez L; Department of Zoology, Genetics and Physical Anthropology, Veterinary Faculty, Universidade de Santiago de Compostela, Lugo, Spain., Nombela-Arrieta C; Department of Medical Oncology and Hematology, University and University Hospital Zurich, Zürich, Switzerland., Espinet E; Department of Pathology and Experimental Therapy, Universidad de Barcelona Facultad de Medicina y Ciencias de La Salud, Barcelona, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), IDIBELL, Barcelona, Spain., Sanchez-Arevalo Lobo VJ; Grupo de Oncología Cutánea, Servicio de Anatomía Patológica, Hospiral Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.; Grupo de Oncología Molecular, Instituto de Investigaciones Biosanitarias, Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Spain., Heeschen C; Pancreatic Cancer Heterogeneity, Candiolo Cancer Institute - FPO - IRCCS, Candiolo (TO), Italy bsainz@iib.uam.es sgsilva@cnio.es christopher.heeschen@icloud.com., Sainz B Jr; Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Cancer Department, Instituto de Investigaciones Biomédicas (IIBM) Sols-Morreale CSIC-UAM, Madrid, Spain bsainz@iib.uam.es sgsilva@cnio.es christopher.heeschen@icloud.com.; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Area 3 Cancer, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.; Área Cáncer, Centro de Investigación Biomédica en Red (CIBERONC), ISCIII, Madrid, Spain.
Publikováno v:
Gut [Gut] 2024 Aug 08; Vol. 73 (9), pp. 1489-1508. Date of Electronic Publication: 2024 Aug 08.
Autor:
Hernando-Requejo O; Radiation Oncology Department, Sanchinarro University Hospital, Madrid, Spain., Olombrada MVT; Radiation Oncology Department, University Hospital Fuenlabrada, Madrid, Spain., Bravo IA; Radiation Oncology Department, 12 de Octubre University Hospital, Madrid, Spain., Moreno LA; Radiation Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain., López-Campos F; Ramón y Cajal University Hospital, Madrid, Spain., Gonzalez ML; Radiation Oncology Department, Sanchinarro University Hospital, Madrid, Spain., Martín MM; Ramón y Cajal University Hospital, Madrid, Spain., Macías VM; Radiation Oncology Department, Provincial Hospital, Castellón, Spain., De la Pinta C; Ramón y Cajal University Hospital, Madrid, Spain.
Publikováno v:
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2024 Jul 22; Vol. 29 (3), pp. 340-347. Date of Electronic Publication: 2024 Jul 22 (Print Publication: 2024).
Autor:
de la Pinta C; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, 28034 Madrid, Spain. Electronic address: carolinadela.pinta@salud.madrid.org.
Publikováno v:
Hepatobiliary & pancreatic diseases international : HBPD INT [Hepatobiliary Pancreat Dis Int] 2024 Feb; Vol. 23 (1), pp. 14-19. Date of Electronic Publication: 2023 Mar 16.
Autor:
de la Pinta, C., Sevillano, D., Colmenares, R., Barrio, S., Olavarria, A., Palomera, A., Romera, R., Cobos, J., Muriel, A., Fernández, E., Perna, LC., Albillos, A., Sancho, S.
Publikováno v:
In Technical Innovations & Patient Support in Radiation Oncology September 2023 27
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
DE LA Pinta C; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., García JD; Medical Physics Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain., Sevillano D; Medical Physics Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain., Colmenares R; Medical Physics Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain., García Latorre R; Radiology Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain., Garví M; Radiation therapist, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain., Pino V; Radiation therapist, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain., Muriel A; Clinical Βiostatistics Unit, Ramón y Cajal University Hospital, IRYCIS, CIBERESP, Universidad de Alcalá, Madrid, Spain., Martín M; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., Fernández E; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., Hernanz R; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., Martín M; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., Domínguez JA; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., Muñóz T; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., Perna LC; Pathology Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain., Albillos A; Department of Gastroenterology, Ramón y Cajal University Hospital, Universidad de Alcalá, IRYCIS, CIBEREHD, Madrid, Spain., Sancho S; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain.
Publikováno v:
Cancer diagnosis & prognosis [Cancer Diagn Progn] 2023 Jul 03; Vol. 3 (4), pp. 433-438. Date of Electronic Publication: 2023 Jul 03 (Print Publication: 2023).
Autor:
Díaz-Alejo JF; Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS); Faculty of Medicine, University of Alcalá de Henares., April-Monn S; Institute of Tissue Medicine and Pathology, University of Bern., Cihova M; Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences., Buocikova V; Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences., Villalón López J; Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS)., Urbanova M; Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences., Lechuga CG; Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO)., Tomas M; Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences; Department of Surgical Oncology, National Cancer Institute, Slovak Medical University., Dubovan P; Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences; Department of Surgical Oncology, National Cancer Institute, Slovak Medical University., Sánchez BL; Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS)., Páez SC; Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS)., Sanjuanbenito A; The Biomedical Research Network in Cancer (CIBERONC); Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal., Lobo E; Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal., Romio de la Heras E; Department of Pathology, Hospital Universitario Ramón y Cajal., Guerra C; The Biomedical Research Network in Cancer (CIBERONC); Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO)., de la Pinta C; Department of Radiation Oncology, Hospital Universitario Ramón y Cajal., Barreto Melian E; Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC)., Rodríguez Garrote M; Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC)., Carrato A; Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC); Faculty of Medicine, University of Alcalá de Henares., Ruiz-Cañas L; Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS); Department of Cancer, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM); Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS., Sainz B Jr; The Biomedical Research Network in Cancer (CIBERONC); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS); Department of Cancer, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM); Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS., Torres A; Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS)., Smolkova B; Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences., Earl J; Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS); julie.earl@live.co.uk.
Publikováno v:
Journal of visualized experiments : JoVE [J Vis Exp] 2023 May 26 (195). Date of Electronic Publication: 2023 May 26.
Autor:
Collado M; Medical Oncology Department, Ramón y Cajal University Hospital-IRYCIS, Alcalá University, 28034 Madrid, Spain., Castillo M; Facultad de Ciencias de la Salud, Universidad Alfonso X El Sabio (UAX), Avenida de la Universidad, 1, 28691 Villanueva de la Cañada, Spain., Muñoz de Mier GJ; Facultad de Ciencias de la Salud, Universidad Alfonso X El Sabio (UAX), Avenida de la Universidad, 1, 28691 Villanueva de la Cañada, Spain., de la Pinta C; Radiation Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Alcalá University, 28034 Madrid, Spain., Peña C; Medical Oncology Department, Ramón y Cajal University Hospital-IRYCIS, Alcalá University, 28034 Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 15; Vol. 24 (8). Date of Electronic Publication: 2023 Apr 15.
Autor:
De La Pinta, C., García, J.D., Sevillano, D., López, A., Nuño, J., Peromingo, R., Ferreiro, M.R., Fuentes, R., Guillén, C., Martínez, I., Reguera, P., Rodriguez, M., Cobos, J., Olavarria, A., Palomera, A., Romera, R., Rojo, J.A., De Cozar, A., Perna, L.C., Albillos, A., Sancho, S.
Publikováno v:
In Radiotherapy and Oncology May 2023 182 Supplement 1:S1571-S1572
Autor:
Valero, M., De la Pinta, C., Centelles, M.E., Mesa, F.L., Fernández, E., Hernánz, R., Martín, M., Muñoz, M.T., Alarza, M., Domínguez, J.A., De Cózar, A., Camacho, M., Azcona, J., Sancho, S.
Publikováno v:
In Radiotherapy and Oncology May 2023 182 Supplement 1:S1003-S1003